Melamine, Hexamethyl-
Melamine, Hexamethyl- Brand names, Melamine, Hexamethyl- Analogs
Melamine, Hexamethyl- Brand Names Mixture
- No information avaliable
Melamine, Hexamethyl- Chemical_Formula
C9H18N6
Melamine, Hexamethyl- RX_link
http://www.rxlist.com/cgi/generic/altretamine.htm
Melamine, Hexamethyl- fda sheet
Melamine, Hexamethyl- msds (material safety sheet)
Melamine, Hexamethyl- Synthesis Reference
No information avaliable
Melamine, Hexamethyl- Molecular Weight
210.28 g/mol
Melamine, Hexamethyl- Melting Point
172-174 oC
Melamine, Hexamethyl- H2O Solubility
91 mg/L
Melamine, Hexamethyl- State
Solid
Melamine, Hexamethyl- LogP
1.566
Melamine, Hexamethyl- Dosage Forms
Capsule
Melamine, Hexamethyl- Indication
For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
Melamine, Hexamethyl- Pharmacology
Altretamine is a novel antineoplastic agent. The precise mechanism by which altretamine exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine and its metabolitics have been negative. Altretamine has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement of cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.
Melamine, Hexamethyl- Absorption
No information avaliable
Melamine, Hexamethyl- side effects and Toxicity
No information avaliable
Melamine, Hexamethyl- Patient Information
No information avaliable
Melamine, Hexamethyl- Organisms Affected
Humans and other mammals
